Infliximab in a patient with treatment-resistant anti-SAE dermatomyositis

Rheumatology (Oxford). 2021 May 14;60(5):e156-e158. doi: 10.1093/rheumatology/keaa698.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Autoantibodies / immunology
  • Dermatologic Agents / therapeutic use*
  • Dermatomyositis / drug therapy*
  • Dermatomyositis / immunology
  • Female
  • Humans
  • Infliximab / therapeutic use*
  • Middle Aged
  • Treatment Outcome
  • Ubiquitin-Activating Enzymes / immunology

Substances

  • Autoantibodies
  • Dermatologic Agents
  • Infliximab
  • SAE1 protein, human
  • Ubiquitin-Activating Enzymes